Baird Reiterates Outperform Rating on Axsome Therapeutics (AXSM)

Baird analyst Joel Beatty reiterated an Outperform rating and $116.00 price target on Axsome Therapeutics (NASDAQ: AXSM)

The analyst comments: "We maintain our Outperform rating, our $116 price target, and our 60% probability of approval for AXS-05 in Alzheimer's disease agitation after the company announced mixed phase 3 results this morning. We believe investors will only give a mixed probability of success to this indication after today's results. It appears to us that the approvability of AXS-05 in Alzheimer's disease agitation (ADA) could remain uncertain into 2026, as an NDA filing is not expected until 2H25."

For an analyst ratings summary and ratings history on Axsome Therapeutics click here. For more ratings news on Axsome Therapeutics click here.

Shares of Axsome Therapeutics closed at $86.70 yesterday.

You May Also Be Interested In

• Citi upgrades AMD to buy with $575 price target ahead of Q4 earnings
• JPMorgan Downgrades Upstream Bio (UPB) to Neutral
• Stifel Downgrades Adobe (ADBE) to Hold